Daily Cosmetic Research Analysis
Three impactful studies span cosmetic surgery outcomes, AI-enabled surgical planning, and patient safety. A meta-analysis finds endoscopic nipple-sparing mastectomy improves cosmetic satisfaction without compromising short- to mid-term oncologic safety. An AI-assisted facial soft-tissue meshing method matches expert quality while reducing processing time to under a minute, and a large series details risks and response to illicit cosmetic botulinum toxin–related iatrogenic botulism.
Summary
Three impactful studies span cosmetic surgery outcomes, AI-enabled surgical planning, and patient safety. A meta-analysis finds endoscopic nipple-sparing mastectomy improves cosmetic satisfaction without compromising short- to mid-term oncologic safety. An AI-assisted facial soft-tissue meshing method matches expert quality while reducing processing time to under a minute, and a large series details risks and response to illicit cosmetic botulinum toxin–related iatrogenic botulism.
Research Themes
- Minimally invasive breast surgery and cosmetic outcomes
- AI-driven preoperative planning in facial reconstructive/cosmetic surgery
- Patient safety and regulation in cosmetic injectables
Selected Articles
1. Oncological, surgical, and cosmetic outcomes of endoscopic versus conventional nipple-sparing mastectomy: meta-analysis.
Across 656 patients in comparative analyses and 2612 in proportional analyses, endoscopic nipple-sparing mastectomy achieved higher cosmetic satisfaction with no detriment in short- to mid-term oncologic outcomes relative to conventional techniques. Single-incision approaches reduced postoperative necrosis risk, though operative time and hospital stay were longer.
Impact: This synthesis provides practice-informing evidence that endoscopic approaches can enhance cosmetic satisfaction without compromising oncologic safety, directly addressing patient-centered outcomes in oncoplastic surgery.
Clinical Implications: Endoscopic nipple-sparing mastectomy can be considered for suitable candidates to improve cosmetic satisfaction, especially single-incision techniques, with counseling on longer operative time and hospital stay.
Key Findings
- No significant differences in oncologic outcomes up to a mean of 52 months between endoscopic and conventional nipple-sparing mastectomy.
- Improved cosmetic satisfaction with endoscopic approaches (OR 1.88; P = 0.020).
- Single-incision endoscopic procedures significantly reduced postoperative necrosis (OR 0.19; P = 0.008).
- Endoscopic procedures were associated with longer operative time (+43.08 min) and hospital stay (+0.72 days).
Methodological Strengths
- Systematic review with Newcastle-Ottawa Scale bias assessment and random-effects meta-analyses.
- Both pairwise comparative and proportional meta-analytic approaches increased robustness.
Limitations
- Non-randomized studies dominate; potential residual confounding.
- Follow-up limited to approximately 4 years on average; long-term oncologic equivalence not established.
- Heterogeneity in surgical technique and learning curves may influence outcomes.
Future Directions: Prospective multicenter registries and randomized trials where feasible should assess long-term oncologic and patient-reported outcomes, including standardized cosmetic metrics and cost-effectiveness.
BACKGROUND: Endoscopic nipple-sparing mastectomy has been developed to improve the cosmetic outcomes of conventional nipple-sparing mastectomy. This meta-analysis compares surgical, quality of life and oncological outcomes of endoscopic nipple-sparing mastectomy versus conventional nipple-sparing mastectomy. METHODS: PubMed and Embase were systematically reviewed to identify literature relevant to endoscopic nipple-sparing mastectomy and conventional nipple-sparing mastectomy literature published through to August 2023. The risk of bias was assessed using the Newcastle-Ottawa Scale, and proportional and pairwise random-effects meta-analysis was performed. Surgical (operative time, duration of hospital stay, blood loss, necrosis, overall complications), quality of life (cosmesis, pain, nipple-areolar complex sensitivity) and oncological outcomes (margin positivity, recurrence, metastasis and breast cancer-specific mortality rate) were evaluated. RESULTS: Of 1286 articles retrieved, 51 endoscopic nipple-sparing mastectomy studies and 12 conventional nipple-sparing mastectomy reviews were analysed; 10 non-randomized comparative studies (656 patients) were included in the pairwise analysis and 36 studies (comparative and single-group cohort studies; 2612 patients) in the proportional meta-analysis. Results showed no differences in oncological outcomes (mean follow-up of up to 52 months), comparable overall (OR = 0.49; P = 0.100) and necrotic complications (OR = 0.45; P = 0.150), and improved cosmetic satisfaction (OR = 1.88; P = 0.020). Comparing only single-incision endoscopic nipple-sparing mastectomy to conventional nipple-sparing mastectomy significantly reduced postoperative necrosis (OR = 0.19; P = 0.008). The proportional meta-analysis produced oncological and surgical outcome rates comparable to or lower than conventional nipple-sparing mastectomy rates. However, longer operative time (weighted mean difference = 43.08 min; P < 0.00001) and duration of hospital stay (weighted mean difference = 0.72 days; P = 0.0007) were observed. CONCLUSION: Endoscopic nipple-sparing mastectomy does not affect oncological outcomes in up to 52 months mean follow-up when compared with conventional nipple-sparing mastectomy and provides better cosmetic satisfaction, with a reduced risk of necrosis after single-incision endoscopic nipple-sparing mastectomy. As such, endoscopic nipple-sparing mastectomy may become a viable breast surgery option.
2. AI-assisted mesh generation for subject-specific modeling of facial soft tissues.
An AI-assisted approach using real-time landmark detection generated subject-specific facial soft-tissue meshes with expert-comparable quality (mean Jacobian ratio 0.83) in under a minute, matching simulation performance of an expert-guided workflow. This substantially reduces manual effort and improves scalability for reconstructive and cosmetic surgical planning.
Impact: This methodological innovation delivers order-of-magnitude time savings without compromising mesh quality, enabling broader access to predictive simulations in clinical workflows.
Clinical Implications: Clinics can integrate automated meshing into surgical planning to expedite simulations for orthognathic and cosmetic procedures, facilitating iterative planning and patient counseling.
Key Findings
- AI-assisted mesh generation achieved a mean Jacobian ratio of 0.83, skewness 0.25, and aspect ratio 2.15, comparable to expert-guided meshing.
- Chamfer distance analyses indicated no significant simulation performance differences between AI-assisted and expert-guided methods.
- Processing time decreased from several hours to under one minute without manual landmarking or mesh edits.
Methodological Strengths
- Head-to-head comparison with a clinically validated expert-guided pipeline.
- Objective mesh quality metrics and geometric similarity (Chamfer distance) analyses.
Limitations
- Single dataset with 29 orthognathic surgery subjects; generalizability to diverse anatomies not established.
- Outcome prediction accuracy was inferred from geometric metrics rather than clinical endpoints.
Future Directions: Validate across multimodal imaging, varied facial phenotypes, and prospective clinical trials linking mesh-driven simulations to postoperative outcomes and patient-reported measures.
PURPOSE: Simulation of reconstructive and cosmetic facial surgeries, such as orthognathic surgery, requires precise, patient-specific soft tissue meshes for outcome prediction. Conventional meshing methods rely on labor-intensive processes, including manual landmark digitization and mesh editing, and often lack point correspondence among subjects. These limitations reduce their efficiency, scalability, and utility in fast-paced clinical environments, highlighting the need for innovative and streamlined meshing techniques. METHODS: This study presents a novel AI-assisted mesh generation (AAMG) approach using Google MediaPipe for real-time facial landmark detection to automate the creation of volumetric meshes of facial soft tissues. By leveraging these landmarks as reference points, the AAMG method generates detailed meshes that accurately reflect individual facial anatomy without manual intervention. To evaluate performance, we compared our automated method with a clinically validated, expert-guided mesh generation (EGMG) method that relies on manual landmark digitization and mesh editing. Both methods were tested on a dataset of 29 subjects who had undergone orthognathic surgery. RESULTS: The AAMG method demonstrated high-quality metrics, with a mean Jacobian ratio of 0.83, skewness of 0.25, and an aspect ratio of 2.15, comparable to the EGMG method. Additionally, Chamfer distance analysis showed no significant differences affecting simulation performance between the two methods. CONCLUSION: The proposed AI-assisted mesh generation method significantly reduces mesh generation time from several hours to under a minute, while maintaining comparable mesh quality and accuracy to a clinically validated, expert-guided mesh generation method. Our method ensures consistent subject-specific meshing by leveraging real-time landmark detection and automated interpolation, improving workflow efficiency for surgical planning.
3. A Retrospective Case Series Study of Illegal Cosmetic Iatrogenic Botulism: Outbreak Analysis and Response Lessons.
Across 161 cases over 10 years, mostly tied to unlicensed providers and counterfeit or unknown botulinum toxin products, severe-to-moderate illness comprised up to 60% with rapid onset after injection. Management included antitoxin and supportive therapies, underscoring urgent needs for surveillance, regulation, and clinician readiness for diagnosis and treatment.
Impact: This is the largest documented series of illicit cosmetic iatrogenic botulism, providing critical epidemiologic and management insights to guide public health surveillance and clinical response.
Clinical Implications: Clinicians should maintain high suspicion for botulism in acute neuromuscular symptoms after cosmetic injections, rapidly initiate antitoxin therapy, and notify public health authorities; regulators should tighten BoNT distribution surveillance and enforce licensing.
Key Findings
- Identified 161 cases of cosmetic iatrogenic botulism over 2014–2024, the largest reported illicit CIB outbreak.
- Majority linked to unknown-origin BoNT administered by unlicensed practitioners in nonmedical settings.
- Severe/moderate disease comprised up to 60%, with peak onset within 3 days post-injection.
- Mean hospital length of stay was 11.64 days; symptoms resolved on average within 24.85 days after treatment.
Methodological Strengths
- Decade-long comprehensive single-center dataset with clinical, laboratory, and therapeutic details.
- Clear description of timelines, severity distribution, and management strategies.
Limitations
- Retrospective single-center design limits generalizability and causal inference.
- Potential under-ascertainment of cases treated elsewhere or not presenting to care.
- Lack of confirmed toxin quantitation/source tracking in all cases.
Future Directions: Establish multicenter surveillance networks and supply-chain tracing for BoNT, standardize clinical pathways for suspected CIB, and evaluate public health interventions to reduce illicit injections.
BACKGROUND: Botulism is a rare and possibly life-threatening neuroparalytic syndrome. Recent large-scale outbreaks of iatrogenic botulism, primarily linked to cosmetic injections, have garnered significant attention. OBJECTIVES: This study discusses the factors that may lead to the outbreak of cosmetic iatrogenic botulism (CIB), provides the epidemiological description of CIB cases, and puts forward response measures. METHODS: All clinical data, laboratory investigations, and therapeutic procedures of CIB patients in a large single-center retrospective cohort (2014-2024) were reviewed and analyzed. RESULTS: Over a 10-year period, 161 cases of CIB were identified, of which 80 (49.69%) were hospitalized and 81 (50.31%) were outpatient cases. Most patients received botulinum toxin (BoNT) injections of unknown origin from unlicensed practitioners in nonmedical settings. Severe and moderate cases of CIB accounted for up to 60%, with the majority of outbreaks occurring in 2024. The median time from botulism onset was 0 to 17 days, with the highest incidence occurring within 3 days following the injection. Hospitalized patients were discharged after a mean of 11.64 ± 9.40 days (range, 1-39 days), and symptoms resolved in botulism patients within a mean of 24.85 ± 11.67 days following treatment. Treatments included antitoxin administration, hyperbaric oxygen therapy, pyridostigmine, other symptomatic treatment, and supportive care. CONCLUSIONS: This represents the largest reported outbreak of illicit CIB worldwide, highlighting the risks associated with counterfeit BoNT, noncompliant practices, and underscoring the critical need for stringent surveillance of BoNT distribution. Clinicians should be adept at recognizing and adhering to the diagnosis, treatment, and follow-up management of CIB.